NASDAQ:PYXS

Pyxis Oncology Stock Insider Trading

Healthcare > Biotechnology

Buy PYXS

*Your capital is at risk

$2.10

-0.0300 (-1.41%)

At Close: Jun 23, 2026

Pyxis Oncology Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.06. In total, the insiders bought 14.4M and sold 97.94K PYXS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	98.06
● Buy	14.4M shares
● Sell	97.94K shares
94% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Mar 24, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 98.06. Confidence increased due to high data reliability score of 90. Supported by overwhelming buy-side pressure (94% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Palani Santhosh Director	Director	45 867 Value: $62.4K
Mar 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Humphrey Rachel Director	Director	45 867 Value: $62.4K
Mar 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Cline Darren S Director	Director	45 867 Value: $62.4K
Mar 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Lewis-hall Freda C Director	Director	45 867 Value: $62.4K
Mar 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Metzger Michael A Director	Director	45 867 Value: $62.4K
Mar 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Flavin John L Director	Director	45 867 Value: $62.4K
Mar 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Wadhane Jitendra Prin Fin & Acct Officer	Officer	262 635 Value: $357.2K
Mar 24, 2026 Buy	Common Stock A-Award	Wadhane Jitendra Prin Fin & Acct Officer	Officer	109 461 Value: $148.9K
Mar 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Dupont Jakob Director	Director	45 867 Value: $62.4K
Feb 03, 2026 Buy	Stock Option (Right to Buy) A-Award	Civik Thomas Interim CEO	CEO / President	690 131 Value: $1.03M
Apr 21, 2025 Sell	Common Stock S-Sale	Humphrey Rachel Director	Director	13 896 Value: $14.4K
Apr 17, 2025 Sell	Common Stock S-Sale	Humphrey Rachel Director	Director	200 Value: $194
Apr 14, 2025 Sell	Common Stock S-Sale	Humphrey Rachel Director	Director	1 400 Value: $1K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Sullivan Lara President ,ceo & Cmo	CEO / President	918 308 Value: $899.9K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Metzger Michael A Director	Director	36 979 Value: $36.2K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Wadhane Jitendra SVP, Chief Accounting Officer	Officer	263 782 Value: $258.5K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Humphrey Rachel Director	Director	36 979 Value: $36.2K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Lewis-hall Freda C Director	Director	36 979 Value: $36.2K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Cline Darren S Director	Director	36 979 Value: $36.2K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Dupont Jakob Director	Director	36 979 Value: $36.2K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Palani Santhosh Director	Director	36 979 Value: $36.2K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Civik Thomas Director	Director	36 979 Value: $36.2K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Connealy Pamela Ann CFO & COO	C-Suite Officer	414 163 Value: $405.9K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Flavin John L Director	Director	36 979 Value: $36.2K
Mar 31, 2025 Buy	Stock Option (Right to Buy) A-Award	Flavin John L Director	Director	36 979 Value: $36.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PYXIS ONCOLOGY, INC.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap...

Read Full Profile Here